We are live on ! Find out more
GRCE

Grace Therapeutics
GRCE

15 hedge funds and large institutions have $7.84M invested in Grace Therapeutics in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

25% more funds holding

Funds holding: 12 → 15 (+3)

23% more capital invested

Capital invested by funds: $6.36M → $7.84M (+$1.47M)

0.31% less ownership

Funds ownership: 20.9% → 20.59% (-0.31%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$770K
2
Renaissance Technologies
Renaissance Technologies
New York
+$91.9K
3
Citadel Advisors
Citadel Advisors
Florida
+$81K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$10

Top Sellers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
-$637K
2
ACM
AIGH Capital Management
Maryland
-$411K
3
TRCT
Tower Research Capital (TRC)
New York
-$4.23K
4
UBS Group
UBS Group
Switzerland
-$84
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
ADAR1 Capital Management
Texas
$2.89M -$637K -185,936 -19%
ACM
2
AIGH Capital Management
Maryland
$1.96M -$411K -120,000 -19%
Bank of America
3
Bank of America
North Carolina
$1.85M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$857K +$770K +225,000 New
Renaissance Technologies
5
Renaissance Technologies
New York
$161K +$91.9K +26,828 +166%
Citadel Advisors
6
Citadel Advisors
Florida
$90.2K +$81K +23,664 New
National Bank of Canada
7
National Bank of Canada
Quebec, Canada
$10.2K – – –
Morgan Stanley
8
Morgan Stanley
New York
$7.04K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$5.6K -$4.23K -1,235 -45%
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$2K +$10 +3 +0.6%
AWM
11
Activest Wealth Management
Florida
$389 – – –
GSWM
12
Golden State Wealth Management
California
$116 +$106 +31 New
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Quebec, Canada
$105 – – –
JP Morgan Chase
14
JP Morgan Chase
New York
$65 – – –
SS
15
SBI Securities
Japan
$4 +$3 +1 New
UBS Group
16
UBS Group
Switzerland
– -$84 -28 Closed

GRCE Hedge Fund Activity: Q4 2024 in Review

15 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2024, worth a combined $7.84M — up 23% from $6.36M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new GRCE positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $770K. The largest seller was ADAR1 Capital Management, cutting an estimated $637K.

  • 15 institutional investors held Grace Therapeutics (GRCE) as of Q4 2024, up from 12 in Q3 2024.
  • Funds reported $7.84M of Grace Therapeutics stock for Q4 2024, up 23% quarter-over-quarter.
  • 4 funds opened new Grace Therapeutics positions in Q4 2024 and 1 closed out, a net change of +3 holders.
  • The largest Grace Therapeutics buyer in Q4 2024 was Vanguard Group, an estimated $770K added.
  • The largest Grace Therapeutics seller in Q4 2024 was ADAR1 Capital Management, an estimated $637K sold.

Based on aggregated 13F filings for Q4 2024.